SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Techniclone (TCLN)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Maurice Winn who wrote (2417)8/13/1998 8:11:00 PM
From: EZLibra  Read Replies (2) of 3702
 
If golfdad doesn't wish it then I won't do it. Furthermore it's not like I'm a frequent poster at CLTR (once) or IDPH (never). It does bother me that each company has been pulling the NZ wool over their shareholders eyes as regards TCLN. The fact that they never mention Techniclone as a perceived competitor in their 10K's is a couple of lawsuits waiting to happen, IMO.

Yet even V1 is thinking a cocktail is the wave to catch for future NHL treatment. What people are missing, IMO, is that the cocktail is likely to be chemo with a MOaB. Chemo successfully treats 60-70% of NHL, Oncolym reaches 80%. Either leaves the imune system intact. That doesn't leave much NHL to treat. Will HMO's pay 10,000 for chemo plus 10,000 for Oncolym plus 10,000 for Rituxan or Y2B8 and a redundant 10,000 for Bexxar? We all focus too much on MOaBs. Who is the dominant player in NHL chemo therapy?

I understand your combo proposition and agree. Will the real HMO world?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News